Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$8.38 USD
-0.51 (-5.71%)
Updated Sep 19, 2025 03:31 PM ET
2-Buy of 5 2
C Value F Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRB 8.38 -0.51(-5.71%)
Will SPRB be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRB
Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
Curis (CRIS) Reports Q2 Loss, Beats Revenue Estimates
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Illumina (ILMN) Q2 Earnings and Revenues Surpass Estimates
Invivyd, Inc. (IVVD) Reports Q4 Loss, Tops Revenue Estimates
Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates
Other News for SPRB
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
Biotech Alert: Searches spiking for these stocks today
12 Health Care Stocks Moving In Monday's Intraday Session